FDA approval of our ANDA for generic Copaxone could happen at any time. We would then be entitled to 50 percent of the profits from generic Copaxone sales.
Are we talking a lot of money here? Hmm...Teva's sales of Copaxone is currently $907 million per year. The cost of treating an MS patient with Copaxone is currently $40,000 per patient per year. I suspect these patients would love to reduce their healthcare costs.
Another $100-$250 million in annual revnues to MNTA's bottom line could do wonders for are price per share. Since we are way under valued right now due to the excessive short position, I think any announcement regarding Copaxone is going to explode the pps.
This is one stock where shorts could get vaporized in less than an hour. They must be watching this stock closer than I do. How do they sleep at night?